
Haemonetics Corporation
- Jurisdiction
United States - LEI
549300ZEL6TXZS6F5F95 - ISIN
US4050241003 (HAE )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€111.29 162.5% undervalued - Financial strength (Piotroski F-Value)
-
8
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Haemonetics Corporation, a healthcare company, provides medical products and solutions. Read full profile
Stock price
Fundamentals
- Net revenue
€1.15B - Gross margin
56.1% - EBIT
€203.52M - EBIT margin
17.6% - Net income
€140.14M - Net margin
12.1%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 10, 2024
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Ray Dalio |
|
|
|
Buy |